Sequella, Inc. is a private, clinical-stage pharmaceutical company focused on addressing the challenge of antibiotic-resistant bacterial diseases through the discovery, development, and commercialization of first-in-class antibiotics with novel mechanisms of action. Their lead drug candidate, SQ109, identified from a proprietary compound library, is currently in Phase 2 clinical trials for the treatment of tuberculosis (TB) and gastritis (Helicobacter pylori infections). In addition, the company acquired a new clinical-stage (Phase 2) oxazolidinone, sutezolid, for the treatment of TB and other resistant bacterial diseases in 2013.
Sequella, Inc. has a robust research program aimed at developing novel antibiotics targeting the enzyme translocase-1, an essential enzyme in all bacteria. The company's product portfolio addresses global health threats and offers significant market opportunity in disease areas with known or suspected infectious etiology, including TB, duodenal ulcers, gastric carcinomas, CDI, Crohn’s Disease, and Chagas Disease.
Founded in 1997, Sequella operates in the Biotechnology and Health Care industries. Their last investment was a $940.94K Venture Round investment on 21 September 2016. The specific investors involved in this round are not provided in the available information.
